{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:58:09Z","timestamp":1790668689025,"version":"4.1.0"},"reference-count":267,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002962"],"award-info":[{"award-number":["82002962"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372819"],"award-info":[{"award-number":["82372819"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20210401076YY"],"award-info":[{"award-number":["20210401076YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020230","name":"Health Commission of Jilin Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Histone deacetylases (HDACs) are key regulators of chromatin architecture and gene expression, and their dysregulation is closely linked to tumorigenesis, making them attractive targets for cancer therapy. Histone deacetylase inhibitors (HDACis) exert broad antitumor effects by modulating both epigenetic and non-epigenetic pathways. Although HDACis have demonstrated clinical activity in selected hematologic malignancies, their limited efficacy as monotherapy and limited therapeutic benefit in many solid tumors continue to constrain their broader clinical utilization. Accumulating evidence suggests that HDACis may have greater clinical value as treatment sensitizers and synergistic partners in combination regimens. Across chemotherapy, radiotherapy, targeted therapy, endocrine therapy, and immunotherapy, they enhance therapeutic responses through a range of interconnected mechanisms, including chromatin relaxation, impairment of DNA damage repair, induction of apoptosis, suppression of cell cycle progression, inhibition of oncogenic signaling pathways, and remodeling of the immune microenvironment. In this review, we outline the classification and biological functions of HDACs, along with an overview of representative HDACis. We focus on the synergistic and sensitizing roles these agents play across major anticancer modalities and discuss the molecular mechanisms underlying their therapeutic effects. We further discuss key translational barriers, including insufficient isoform selectivity, off-target toxicity, tumor heterogeneity, and inefficient drug delivery. Finally, we highlight emerging strategies\u2014including isoform-selective inhibitors, mechanism-based biomarkers, rationally designed combinations, targeted delivery platforms, and dual- or multi-target agents. Overall, this review provides a comprehensive overview of HDACi-based combination therapies and their therapeutic and translational implications.<\/jats:p>","DOI":"10.3389\/fcell.2026.1951750","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:41:43Z","timestamp":1790667703000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges"],"prefix":"10.3389","volume":"14","author":[{"given":"Kun-Yao","family":"Liu","sequence":"first","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Laboratory of Organ Regeneration and Transplantation of The Ministry of Education","place":["Changchun, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Cancer Research Institute of Jilin University, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"International Center of Future Science, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Laboratory of Organ Regeneration and Transplantation of The Ministry of Education","place":["Changchun, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Cancer Research Institute of Jilin University, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Laboratory of Organ Regeneration and Transplantation of The Ministry of Education","place":["Changchun, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Cancer Research Institute of Jilin University, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Laboratory of Organ Regeneration and Transplantation of The Ministry of Education","place":["Changchun, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Cancer Research Institute of Jilin University, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ying","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Hebei University of Engineering","place":["Handan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Laboratory of Organ Regeneration and Transplantation of The Ministry of Education","place":["Changchun, China"]},{"name":"China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"Cancer Research Institute of Jilin University, The First Hospital of Jilin University","place":["Changchun, China"]},{"name":"International Center of Future Science, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1039\/d5ra09034b","article-title":"HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives","volume":"16","author":"Abdallah","year":"2026","journal-title":"RSC Adv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"701671","DOI":"10.3389\/fimmu.2021.701671","article-title":"Synergistic tumor cytolysis by NK cells in combination with a Pan-HDAC inhibitor, panobinostat","volume":"12","author":"Afolabi","year":"2021","journal-title":"Front. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett."},{"key":"B7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41419-021-03697-6","article-title":"EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function","volume":"12","author":"Bahl","year":"2021","journal-title":"Cell Death Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"111777","DOI":"10.1016\/j.cbi.2025.111777","article-title":"The novel selective HDAC1 inhibitor ZJH-1 exhibits potent antitumor activity in castration-resistant prostate cancer, potentially involving HSP90AA1","volume":"421","author":"Bao","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"B9","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"35880","DOI":"10.1038\/s41598-025-19717-w","article-title":"Adverse drug reaction profiles of histone deacetylase inhibitors","volume":"15","author":"Begum","year":"2025","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3390\/pharmaceutics15112581","article-title":"Targeting histone deacetylases 6 in dual-target therapy of cancer","volume":"15","author":"Beljkas","year":"2023","journal-title":"Pharmaceutics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","article-title":"Romidepsin: a novel histone deacetylase inhibitor for cancer","volume":"20","author":"Bertino","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"Bolden","year":"2013","journal-title":"Cell Death Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3390\/cells13191644","article-title":"The structures, functions, and roles of class III HDACs (Sirtuins) in neuropsychiatric diseases","volume":"13","author":"Bonomi","year":"2024","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s43018-025-01004-2","article-title":"Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and\/or metastatic squamous cell carcinomas: a phase 2 basket trial","volume":"6","author":"Borcoman","year":"2025","journal-title":"Nat. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.1093\/nar\/gkaa613","article-title":"Nucleosomes effectively shield DNA from radiation damage in living cells","volume":"48","author":"Brambilla","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ymthe.2024.01.002","article-title":"CTLA-4: checkpoints beyond the membrane","volume":"32","author":"Buchan","year":"2024","journal-title":"Mol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3390\/medicina61071280","article-title":"Current endocrine therapy in hormone-receptor-positive breast cancer: from tumor biology to the rationale for therapeutic tunning","volume":"61","author":"Burciu","year":"2025","journal-title":"Med. Kaunas."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1200\/jco.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-Cell lymphoma: final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/onc.2015.46","article-title":"Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity","volume":"34","author":"Cao","year":"2015","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1038\/s41467-025-64081-y","article-title":"A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice","volume":"16","author":"Cao","year":"2025","journal-title":"Nat. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1078-0432.Ccr-14-2701","article-title":"HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL","volume":"21","author":"Carson","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41420-024-02115-y","article-title":"HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks","volume":"10","author":"Cassandri","year":"2024","journal-title":"Cell Death Discov."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers15061769","article-title":"Antiandrogen-equipped histone deacetylase inhibitors selectively inhibit androgen receptor (AR) and AR-Splice variant (AR-SV) in castration-resistant prostate cancer (CRPC)","volume":"15","author":"Chandrasekaran","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13148-019-0681-6","article-title":"Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status","volume":"11","author":"Chao","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/1541-7786.Mcr-11-0587","article-title":"Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma","volume":"10","author":"Chen","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1615\/critrevoncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"Chen","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1021\/acs.jmedchem.8b01825","article-title":"Discovery of novel dual histone deacetylase and mammalian target of rapamycin target inhibitors as a promising strategy for cancer therapy","volume":"62","author":"Chen","year":"2019","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"16354","DOI":"10.1038\/s41598-021-95837-3","article-title":"HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/2326-6066.Cir-18-0070","article-title":"Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1341031","DOI":"10.1080\/2162402x.2017.1341031","article-title":"Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice","volume":"6","author":"Chu","year":"2017","journal-title":"Oncoimmunology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ejmech.2018.09.024","article-title":"Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat","volume":"158","author":"Chu-Farseeva","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"15738","DOI":"10.1021\/acs.jmedchem.5c00717","article-title":"Structure-based discovery of Hsp90\/HDAC6 dual inhibitors targeting aggressive prostate cancer","volume":"68","author":"Citarella","year":"2025","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2313137120","DOI":"10.1073\/pnas.2313137120","article-title":"SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status","volume":"120","author":"Daley","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/1535-7163.Mct-18-1068","article-title":"HDAC3 inhibition upregulates PD-L1 expression in B-Cell lymphomas and augments the efficacy of Anti-PD-L1 therapy","volume":"18","author":"Deng","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"56199","DOI":"10.18632\/oncotarget.14147","article-title":"A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors","volume":"8","author":"Deutsch","year":"2017","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/sj.bjc.6605969","article-title":"Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase","volume":"103","author":"Di Gennaro","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.09.018","article-title":"Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer","volume":"329","author":"Diyabalanage","year":"2013","journal-title":"Cancer Lett."},{"key":"B47","doi-asserted-by":"publisher","first-page":"580328","DOI":"10.3389\/fimmu.2020.580328","article-title":"Chimeric antigen receptor T cells targeting NKG2D-Ligands show robust efficacy against acute myeloid leukemia and T-Cell acute lymphoblastic leukemia","volume":"11","author":"Driouk","year":"2020","journal-title":"Front. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41419-023-06205-0","article-title":"Targeting the E2F1\/Rb\/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth","volume":"14","author":"Duan","year":"2023","journal-title":"Cell Death Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/jco.21.00703","article-title":"Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT consortium","volume":"39","author":"DuBois","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"eadd3243","DOI":"10.1126\/sciadv.add3243","article-title":"HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer","volume":"9","author":"Eichner","year":"2023","journal-title":"Sci. Adv."},{"key":"B52","doi-asserted-by":"publisher","first-page":"114774","DOI":"10.1016\/j.biopha.2023.114774","article-title":"Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin","volume":"164","author":"El Omari","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/0008-5472.Can-19-0040","article-title":"HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy","volume":"79","author":"Emmons","year":"2019","journal-title":"Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.3892\/or.2020.7806","article-title":"Radiosensitizing effects of c-myc gene knockdown-induced G2\/M phase arrest by intrinsic stimuli via the mitochondrial signaling pathway","volume":"44","author":"Fan","year":"2020","journal-title":"Oncol. Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1158\/1078-0432.Ccr-07-2114","article-title":"Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications","volume":"13","author":"Fantin","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.canlet.2014.02.012","article-title":"Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer","volume":"347","author":"Feng","year":"2014","journal-title":"Cancer Lett."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1002\/med.21972","article-title":"Histone deacetylase-based dual targeted inhibition in multiple myeloma","volume":"43","author":"Ferro","year":"2023","journal-title":"Med. Res. Rev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1038\/bjc.2013.691","article-title":"HDAC inhibitor confers radiosensitivity to prostate stem-like cells","volume":"109","author":"Frame","year":"2013","journal-title":"Br. J. Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/bjh.13318","article-title":"Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents","volume":"169","author":"Frys","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12026-026-09756-4","article-title":"The Fas-FasL system: from apoptosis regulator to therapeutic target in autoimmunity, cancer, and transplantation","volume":"74","author":"Gadelkarim","year":"2026","journal-title":"Immunol. Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"157\u2013e121","DOI":"10.1634\/theoncologist.2017-0501","article-title":"Phase II study of bevacizumab and vorinostat for patients with recurrent world health organization grade 4 malignant glioma","volume":"23","author":"Ghiaseddin","year":"2018","journal-title":"Oncologist"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1158\/1078-0432.Ccr-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"B68","doi-asserted-by":"publisher","first-page":"786120","DOI":"10.3389\/fonc.2021.786120","article-title":"Phase Ib study of the histone deacetylase 6 inhibitor citarinostat in combination with paclitaxel in patients with advanced solid tumors","volume":"11","author":"Gordon","year":"2021","journal-title":"Front. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3892\/ijo.2015.2996","article-title":"The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells","volume":"47","author":"Groh","year":"2015","journal-title":"Int. J. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair","volume":"108","author":"Groselj","year":"2013","journal-title":"Br. J. Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1021\/cb400542w","article-title":"Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors","volume":"8","author":"Gryder","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-025-02124-y","article-title":"Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets","volume":"10","author":"Guan","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41401-024-01236-5","article-title":"Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations","volume":"45","author":"Hao","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"B74","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s12253-020-00834-y","article-title":"HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line","volume":"26","author":"Heged\u0171s","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1021\/acs.jmedchem.7b01444","article-title":"Controlling plasma stability of hydroxamic acids: a MedChem toolbox","volume":"60","author":"Hermant","year":"2017","journal-title":"J. Med. Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1260545","DOI":"10.3389\/fimmu.2023.1260545","article-title":"Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy","volume":"14","author":"Holay","year":"2023","journal-title":"Front. Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-017-0434-3","article-title":"Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines","volume":"10","author":"H\u00f6lscher","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"B79","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.Cd-20-0873","article-title":"Durable suppression of acquired MEK inhibitor resistance in cancer by sequestering MEK from ERK and promoting Antitumor T-cell immunity","volume":"11","author":"Hong","year":"2021","journal-title":"Cancer Discov."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/blood-2009-11-256354","article-title":"Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound \u03b2-phenylethyl isothiocyanate","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"444","DOI":"10.21147\/j.issn.1000-9604.2016.04.08","article-title":"A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer","volume":"28","author":"Hu","year":"2016","journal-title":"Chin. J. Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"116696","DOI":"10.1016\/j.ejmech.2024.116696","article-title":"Overview of class I HDAC modulators: inhibitors and degraders","volume":"276","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.18632\/oncotarget.27546","article-title":"Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway","volume":"11","author":"Idso","year":"2020","journal-title":"Oncotarget"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of Cisplatin-DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1535-7163.Mct-22-0101","article-title":"Genotype-Tailored ERK\/MAPK pathway and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death","volume":"22","author":"Jenkins","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/s1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41698-025-00949-y","article-title":"HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype","volume":"9","author":"Jiang","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1533044","DOI":"10.3389\/fimmu.2025.1533044","article-title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","volume":"16","author":"Jo","year":"2025","journal-title":"Front. Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e53100","DOI":"10.1371\/journal.pone.0053100","article-title":"Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo","volume":"8","author":"Juengel","year":"2013","journal-title":"PLoS One"},{"key":"B91","doi-asserted-by":"publisher","first-page":"110016","DOI":"10.18632\/oncotarget.22454","article-title":"HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells","volume":"8","author":"Juengel","year":"2017","journal-title":"Oncotarget"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1021\/cr068207j","article-title":"Direct cellular responses to platinum-induced DNA damage","volume":"107","author":"Jung","year":"2007","journal-title":"Chem. Rev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"Kalac","year":"2011","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3390\/cancers13143575","article-title":"HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity","volume":"13","author":"Karagiannis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B96","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"31127","DOI":"10.1074\/jbc.274.44.31127","article-title":"Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase","volume":"274","author":"Kim","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B98","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/bcr2562","article-title":"Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein","volume":"12","author":"Kim","year":"2010","journal-title":"Breast Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.nucmedbio.2013.06.007","article-title":"Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET","volume":"40","author":"Kim","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.0105-2896.2006.00391.x","article-title":"CD8+ T-cell memory in tumor immunology and immunotherapy","volume":"211","author":"Klebanoff","year":"2006","journal-title":"Immunol. Rev."},{"key":"B102","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells","volume":"9","author":"Knox","year":"2019","journal-title":"Sci. Rep."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1158\/0008-5472.Can-15-2104","article-title":"Cell cycle-dependent mechanisms underlie vincristine-induced death of primary acute lymphoblastic leukemia cells","volume":"76","author":"Kothari","year":"2016","journal-title":"Cancer Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1182\/bloodadvances.2020002049","article-title":"The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1","volume":"4","author":"Kruglov","year":"2020","journal-title":"Blood Adv."},{"key":"B105","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"17335","DOI":"10.1073\/pnas.0706487104","article-title":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases","volume":"104","author":"Lahm","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B107","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40425-019-0517-0","article-title":"HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics","volume":"7","author":"Laino","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-021-00407-5","article-title":"Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed\/refractory multiple myeloma","volume":"11","author":"Laubach","year":"2021","journal-title":"Blood Cancer J."},{"key":"B109","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/ijms22031341","article-title":"HDAC6-Selective inhibitor overcomes bortezomib resistance in multiple myeloma","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol. Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1158\/1078-0432.Ccr-20-2487","article-title":"A pan-histone deacetylase inhibitor enhances the antitumor activity of B7-H3-Specific CAR T cells in solid tumors","volume":"27","author":"Lei","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.freeradbiomed.2015.07.155","article-title":"Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway","volume":"89","author":"Leone","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.1093\/nar\/gky568","article-title":"Histone H1 acetylation at lysine 85 regulates chromatin condensation and genome stability upon DNA damage","volume":"46","author":"Li","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"B118","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-023-00573-9","article-title":"HDAC1\/2\/3 are major histone desuccinylases critical for promoter desuccinylation","volume":"9","author":"Li","year":"2023","journal-title":"Cell Discov."},{"key":"B119","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","article-title":"A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors","volume":"103","author":"Li","year":"","journal-title":"Ann. Hematol."},{"key":"B120","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-202471","volume-title":"A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP Regimen) in Combination with Radiotherapy as First-Line Treatment in High-Risk Stages I and II of Extranodal NK\/T-Cell Lymphoma","author":"Li","year":""},{"key":"B121","doi-asserted-by":"publisher","first-page":"1662145","DOI":"10.3389\/fimmu.2025.1662145","article-title":"Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1021\/acs.jmedchem.8b01597","article-title":"Discovery of novel Janus Kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B125","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","article-title":"Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e145035","DOI":"10.1172\/jci145035","article-title":"Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Invest"},{"key":"B127","doi-asserted-by":"publisher","first-page":"12200","DOI":"10.1021\/acs.jmedchem.2c00866","article-title":"Discovery of novel src Homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor immunity","volume":"65","author":"Liu","year":"","journal-title":"J. Med. Chem."},{"key":"B128","doi-asserted-by":"publisher","first-page":"972020","DOI":"10.3389\/fcell.2022.972020","article-title":"Lactylation, an emerging hallmark of metabolic reprogramming: current progress and open challenges","volume":"10","author":"Liu","year":"","journal-title":"Front. Cell Dev. Biol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"115418","DOI":"10.1016\/j.biopha.2023.115418","article-title":"HDAC11: a novel target for improved cancer therapy","volume":"166","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/leu.2017.130","article-title":"Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response","volume":"31","author":"Long","year":"2017","journal-title":"Leukemia"},{"key":"B131","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/1078-0432.Ccr-08-2714","article-title":"Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma","volume":"15","author":"Lopez","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.Ccr-18-3989","article-title":"Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas","volume":"25","author":"Lue","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.3390\/ijms21228828","article-title":"Structure-based inhibitor discovery of class I histone deacetylases (HDACs)","volume":"21","author":"Luo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"663384","DOI":"10.3389\/fncel.2021.663384","article-title":"HDAC4 knockdown alleviates denervation-induced muscle atrophy by inhibiting myogenin-dependent atrogene activation","volume":"15","author":"Ma","year":"2021","journal-title":"Front. Cell Neurosci."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41588-019-0514-8","article-title":"HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype","volume":"51","author":"Malhotra","year":"2019","journal-title":"Nat. Genet."},{"key":"B137","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.canlet.2019.07.009","article-title":"Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines","volume":"461","author":"Marampon","year":"2019","journal-title":"Cancer Lett."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e005871","DOI":"10.1136\/jitc-2022-005871","article-title":"Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation","volume":"11","author":"Marquardt","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41419-023-06319-5","article-title":"Class IIa HDACs inhibit cell death pathways and protect muscle integrity in response to lipotoxicity","volume":"14","author":"Martin","year":"2023","journal-title":"Cell Death Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","article-title":"Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma","volume":"21","author":"Mazur","year":"2015","journal-title":"Nat. Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/leu.2012.342","article-title":"Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia","volume":"27","author":"Mims","year":"2013","journal-title":"Leukemia"},{"key":"B144","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B145","doi-asserted-by":"publisher","first-page":"eabi6696","DOI":"10.1126\/sciadv.abi6696","article-title":"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases","volume":"8","author":"Moreno-Yruela","year":"2022","journal-title":"Sci. Adv."},{"key":"B146","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B147","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3390\/ijms20102415","article-title":"p53 at the crossroads between different types of HDAC inhibitor-mediated cancer cell death","volume":"20","author":"Mrakovcic","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"624914","DOI":"10.3389\/fcell.2021.624914","article-title":"The regulation and function of histone crotonylation","volume":"9","author":"Ntorla","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1111\/febs.15895","article-title":"HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes","volume":"289","author":"N\u00fa\u00f1ez-\u00c1lvarez","year":"2022","journal-title":"Febs J."},{"key":"B151","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.Ccr-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B152","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1038\/s41467-019-13210-5","article-title":"Rpd3L and Hda1 histone deacetylases facilitate repair of broken forks by promoting sister chromatid cohesion","volume":"10","author":"Ortega","year":"2019","journal-title":"Nat. Commun."},{"key":"B153","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol. Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bjh.16160","article-title":"Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in hodgkin and T-cell lymphoma","volume":"188","author":"Passero","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B157","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/jat.1395","article-title":"Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties","volume":"29","author":"Polak","year":"2009","journal-title":"J. Appl. Toxicol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"218011","DOI":"10.1016\/j.canlet.2025.218011","article-title":"TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia","volume":"633","author":"Pottier","year":"2025","journal-title":"Cancer Lett."},{"key":"B160","doi-asserted-by":"publisher","first-page":"105274","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"e05951","DOI":"10.1002\/adma.202505951","article-title":"Dual targeting of m(7)G tRNA modification and histone acetylation using carrier-free nano-epidrugs to evoke osteosarcoma chemosensitization","volume":"38","author":"Qi","year":"2026","journal-title":"Adv. Mater"},{"key":"B162","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1158\/1535-7163.Mct-06-0111","article-title":"Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies","volume":"5","author":"Qian","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e2401142","DOI":"10.1002\/advs.202401142","article-title":"HDAC8 enhances the function of HIF-2\u03b1 by deacetylating ETS1 to decrease the sensitivity of TKIs in ccRCC","volume":"11","author":"Qian","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B164","doi-asserted-by":"publisher","first-page":"e001696","DOI":"10.1136\/jitc-2020-001696","article-title":"Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma","volume":"9","author":"Que","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13058-015-0533-z","article-title":"Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression","volume":"17","author":"Raha","year":"2015","journal-title":"Breast Cancer Res."},{"key":"B166","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/jco.2009.24.9094","article-title":"Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1021\/jacsau.4c00828","article-title":"Slow-binding and covalent HDAC inhibition: a new paradigm?","volume":"4","author":"Raouf","year":"2024","journal-title":"JACS Au"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2217\/fon.15.62","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"11","author":"Rashidi","year":"2015","journal-title":"Future Oncol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in hydrazide-based HDAC inhibitors: a review of recent developments and therapeutic potential","volume":"68","author":"Raucci","year":"2025","journal-title":"J. Med. Chem."},{"key":"B170","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1470-2045(10)70058-9","article-title":"Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the pelvic radiation and vorinostat (PRAVO) phase 1 study","volume":"11","author":"Ree","year":"2010","journal-title":"Lancet Oncol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1021\/mp200329f","article-title":"Histone deacetylase inhibitors: emerging mechanisms of resistance","volume":"8","author":"Robey","year":"2011","journal-title":"Mol. Pharm."},{"key":"B172","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.Ccr-19-2214","article-title":"A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B174","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/ng1773","article-title":"A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition","volume":"38","author":"Ropero","year":"2006","journal-title":"Nat. Genet."},{"key":"B175","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1189\/jlb.0711339","article-title":"Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression","volume":"91","author":"Rossi","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","article-title":"Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma","volume":"7","author":"Ruan","year":"2023","journal-title":"Blood Adv."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1535-7163.Mct-13-0345","article-title":"HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2","volume":"12","author":"Sabnis","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B179","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.bbapap.2009.09.009","article-title":"Structural basis for sirtuin function: what we know and what we don't","volume":"1804","author":"Sanders","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B181","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e3002038","DOI":"10.1371\/journal.pbio.3002038","article-title":"Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC","volume":"21","author":"Schade","year":"2023","journal-title":"PLoS Biol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.3390\/ijms24065553","article-title":"Synergistic interaction of the class IIa HDAC Inhibitor CHDI0039 with Bortezomib in head and neck cancer cells","volume":"24","author":"Schrenk","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B184","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.1038\/s41467-025-62934-0","article-title":"The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active","volume":"16","author":"Sequera","year":"2025","journal-title":"Nat. Commun."},{"key":"B185","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"B187","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/1078-0432.Ccr-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B188","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13148-019-0800-4","article-title":"Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells","volume":"12","author":"Sharda","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"B189","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jsbmb.2017.08.007","article-title":"Estradiol (E2)- and tamoxifen (Tmx)-bound ER-alpha (ER\u03b1) interact differentially with histone deacetylases 1 and 3 (HDACs 1 and 3)","volume":"174","author":"Sharma","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"e30815","DOI":"10.1371\/journal.pone.0030815","article-title":"Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"key":"B192","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"115938","DOI":"10.1016\/j.ejmech.2023.115938","article-title":"Dual inhibitors of HDAC and other epigenetic regulators: a novel strategy for cancer treatment","volume":"263","author":"Shirbhate","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/13543776.2025.2546595","article-title":"An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 - present): part 1-patent granted","volume":"35","author":"Shukla","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"B195","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1073\/pnas.0510341103","article-title":"The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases","volume":"103","author":"Simonini","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B197","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ijrobp.2009.08.031","article-title":"Suberoylanilide hydroxyamic acid modification of chromatin architecture affects DNA break formation and repair","volume":"76","author":"Singh","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B198","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.3390\/molecules25194394","article-title":"Bifunctional HDAC therapeutics: one drug to rule them all?","volume":"25","author":"Smalley","year":"2020","journal-title":"Molecules"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/0008-5472.Can-18-2738","article-title":"AKT as a therapeutic target for cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharm. (Basel)"},{"key":"B201","doi-asserted-by":"publisher","first-page":"e010460","DOI":"10.1136\/jitc-2024-010460","article-title":"HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAF(V600E)-mutant microsatellite stable colorectal cancer","volume":"13","author":"Sun","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B202","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat. Med."},{"key":"B204","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.272.5260.408","article-title":"A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p","volume":"272","author":"Taunton","year":"1996","journal-title":"Science"},{"key":"B205","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s10637-018-0696-4","article-title":"A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma","volume":"37","author":"Teknos","year":"2019","journal-title":"Invest New Drugs"},{"key":"B206","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-011-1364-y","article-title":"Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy","volume":"130","author":"Thomas","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B207","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/annonc\/mdw044","article-title":"A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma","volume":"27","author":"Thomas","year":"2016","journal-title":"Ann. Oncol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/1535-7163.Mct-12-1242","article-title":"Histone deacetylase regulation of ATM-mediated DNA damage signaling","volume":"12","author":"Thurn","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B209","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semcancer.2025.05.008","article-title":"HDAC inhibitors: cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury","volume":"113","author":"To","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B211","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/cancers10060200","article-title":"Overcoming resistance of human non-hodgkin's lymphoma to CD19-CAR CTL therapy by Celecoxib and histone deacetylase inhibitors","volume":"10","author":"Torres-Collado","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B212","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/jci137074","article-title":"The black sheep of class IIa: HDAC7 SIKens the heart","volume":"130","author":"Travers","year":"2020","journal-title":"J. Clin. Invest"},{"key":"B213","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/s41416-023-02195-0","article-title":"Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling","volume":"128","author":"Tsai","year":"2023","journal-title":"Br. J. Cancer"},{"key":"B214","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.18632\/oncotarget.28278","article-title":"HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs","volume":"13","author":"Valdez","year":"2022","journal-title":"Oncotarget"},{"key":"B216","doi-asserted-by":"publisher","first-page":"9241","DOI":"10.3390\/ijms25179241","article-title":"Synergistic cytotoxicity of histone deacetylase and Poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: implications for novel therapeutic combinations","volume":"25","author":"Valdez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B217","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4161\/cbt.6.2.3578","article-title":"Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells","volume":"6","author":"Valentini","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"B218","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.trecan.2017.04.004","article-title":"Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity","volume":"3","author":"Wainwright","year":"2017","journal-title":"Trends Cancer"},{"key":"B220","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","article-title":"Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"B222","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.biomaterials.2015.02.015","article-title":"Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors","volume":"51","author":"Wang","year":"2015","journal-title":"Biomaterials"},{"key":"B223","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/or.2016.4811","article-title":"HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma","volume":"36","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"key":"B224","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2017.04.028","article-title":"In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor","volume":"400","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"B225","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1158\/2326-6066.Cir-19-0619","article-title":"Histone deacetylase inhibitors and IL21 cooperate to Reprogram Human Effector CD8(+) T cells to memory T cells","volume":"8","author":"Wang","year":"","journal-title":"Cancer Immunol. Res."},{"key":"B226","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"","journal-title":"Mol. Cancer"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.21037\/jgo-21-560","article-title":"Trichostatin A enhances radiosensitivity and radiation-induced DNA damage of esophageal cancer cells","volume":"12","author":"Wang","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.26499","article-title":"Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial","volume":"97","author":"Wang","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/2159-8290.Cd-24-1033","article-title":"Vascular normalization augments the antitumor efficacy of combined HDAC inhibitor with immunotherapy in solid tumors","volume":"15","author":"Wang","year":"2025","journal-title":"Cancer Discov."},{"key":"B231","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13046-025-03613-2","article-title":"Low expression of ALOX15B modulates immunosuppressive tumor microenvironment in diffuse large B-cell lymphoma via the TAP1\/MHC-I axis","volume":"45","author":"Wang","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B232","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cr.2017.68","article-title":"Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription","volume":"27","author":"Wei","year":"2017","journal-title":"Cell Res."},{"key":"B233","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/0008-5472.Can-08-2216","article-title":"Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer","volume":"69","author":"Welsbie","year":"2009","journal-title":"Cancer Res."},{"key":"B234","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.Cir-15-0077-t","article-title":"HDAC inhibition upregulates PD-1 ligands in Melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B236","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41389-021-00331-0","article-title":"A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo","volume":"10","author":"Wu","year":"2021","journal-title":"Oncogenesis"},{"key":"B237","doi-asserted-by":"publisher","first-page":"102461","DOI":"10.1016\/j.redox.2022.102461","article-title":"HDAC11 negatively regulates antifungal immunity by inhibiting Nos2 expression via binding with transcriptional repressor STAT3","volume":"56","author":"Wu","year":"","journal-title":"Redox Biol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"","journal-title":"Signal Transduct. Target Ther."},{"key":"B239","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-026-02632-5","article-title":"HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4\/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)","volume":"11","author":"Wu","year":"2026","journal-title":"Signal Transduct. Target Ther."},{"key":"B240","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"B241","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7534\/j.issn.1009-2137.2015.02.030","article-title":"Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response","volume":"23","author":"Xu","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B242","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/hum.2018.119","article-title":"Induced CD20 expression on B-Cell malignant cells heightened the cytotoxic activity of chimeric antigen receptor engineered T cells","volume":"30","author":"Xu","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B243","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3892\/etm.2022.11512","article-title":"Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis","volume":"24","author":"Xu","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"B244","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B245","doi-asserted-by":"publisher","first-page":"116331","DOI":"10.1016\/j.bcp.2024.116331","article-title":"Comprehensive review of histone lactylation: structure, function, and therapeutic targets","volume":"225","author":"Xu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-025-03335-5","article-title":"CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages","volume":"44","author":"Xu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B247","doi-asserted-by":"publisher","first-page":"101343","DOI":"10.1016\/j.drup.2025.101343","article-title":"Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis","volume":"85","author":"Xu","year":"2026","journal-title":"Drug Resist Updat"},{"key":"B248","doi-asserted-by":"publisher","first-page":"101700","DOI":"10.1016\/j.lanwpc.2025.101700","article-title":"Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial","volume":"63","author":"Xue","year":"2025","journal-title":"Lancet Reg. Health West Pac"},{"key":"B249","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molimm.2019.01.014","article-title":"Fas\/FasL signaling is critical for the survival of exhausted antigen-specific CD8(+) T cells during tumor immune response","volume":"107","author":"Yajima","year":"2019","journal-title":"Mol. Immunol."},{"key":"B250","doi-asserted-by":"publisher","first-page":"11171","DOI":"10.1074\/jbc.M809268200","article-title":"p53 acetylation is crucial for its transcription-independent proapoptotic functions","volume":"284","author":"Yamaguchi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B251","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1182\/blood.v130.suppl_1.945.945","article-title":"GATA-1 deacetylation and interaction with HDAC1 is critical for GATA-1 mediated gene transcription","volume":"130","author":"Yan","year":"2017","journal-title":"Blood"},{"key":"B252","doi-asserted-by":"publisher","first-page":"9783","DOI":"10.1093\/nar\/gkab737","article-title":"HDAC1 is required for GATA-1 transcription activity, global chromatin occupancy and hematopoiesis","volume":"49","author":"Yan","year":"2021","journal-title":"Nucleic Acids Research"},{"key":"B253","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.canlet.2017.12.005","article-title":"HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH\/Gli1 signaling pathway","volume":"415","author":"Yang","year":"2018","journal-title":"Cancer Lett."},{"key":"B254","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41467-020-20874-x","article-title":"CTLA-4 expression by B-1a B cells is essential for immune tolerance","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"B255","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.1016\/j.intimp.2025.114268","article-title":"A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: clinical safety, efficacy, and correlative analysis","volume":"151","author":"Yang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41420-025-02756-7","article-title":"Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic I\u03baB\u03b1 stabilization in p53-mutant diffuse large B-cell lymphoma","volume":"11","author":"Yao","year":"2025","journal-title":"Cell Death Discov."},{"key":"B257","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1002\/anie.201701144","article-title":"Chromatin regulates genome targeting with Cisplatin","volume":"56","author":"Zacharioudakis","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B258","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4161\/cbt.29452","article-title":"Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors","volume":"15","author":"Zang","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"B259","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s43018-022-00489-5","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat. Cancer"},{"key":"B260","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer Cell"},{"key":"B261","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4161\/cbt.8.9.8143","article-title":"Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells","volume":"8","author":"Zhang","year":"","journal-title":"Cancer Biol. Ther."},{"key":"B262","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/JTO.0b013e318194fae7","article-title":"Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines","volume":"4","author":"Zhang","year":"","journal-title":"J. Thorac. Oncol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-020-0298-1","article-title":"Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Blood Cancer J."},{"key":"B264","doi-asserted-by":"publisher","first-page":"116930","DOI":"10.1016\/j.biopha.2024.116930","article-title":"Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B265","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.1200\/JCO.2025.43.16_suppl.11560","article-title":"A phase II, multicenter trial of the combination of chidamide and toripalimab in patients with advanced soft tissue sarcoma: efficacy updates","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol"},{"key":"B266","doi-asserted-by":"publisher","first-page":"e70202","DOI":"10.1002\/mco2.70202","article-title":"Targeting the enhanced sensitivity of radiotherapy in cancer: mechanisms, applications, and challenges","volume":"6","author":"Zhao","year":"2025","journal-title":"MedComm"},{"key":"B267","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41422-025-01205-5","article-title":"Tumor PD-L1 induces \u03b22m ubiquitylation and degradation for cancer cell immune evasion","volume":"36","author":"Zhao","year":"2026","journal-title":"Cell Res."},{"key":"B268","doi-asserted-by":"publisher","first-page":"109753","DOI":"10.1016\/j.intimp.2023.109753","article-title":"Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway","volume":"116","author":"Zheng","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B269","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/0008-5472.Can-22-1270","article-title":"The HDAC2-SP1 axis orchestrates protumor macrophage polarization","volume":"83","author":"Zheng","year":"","journal-title":"Cancer Res."},{"key":"B270","doi-asserted-by":"publisher","first-page":"113825","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B271","doi-asserted-by":"publisher","first-page":"eabo4356","DOI":"10.1126\/scisignal.abo4356","article-title":"Degradation of HDAC10 by autophagy promotes IRF3-mediated antiviral innate immune responses","volume":"15","author":"Zhou","year":"2022","journal-title":"Sci. Signal"},{"key":"B272","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/molecules29112623","article-title":"Trichostatin A promotes cytotoxicity of cisplatin, as evidenced by enhanced Apoptosis\/Cell death markers","volume":"29","author":"Zhou","year":"2024","journal-title":"Molecules"},{"key":"B273","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/ph18040563","article-title":"Histone deacetylase inhibitors promote the anticancer activity of cisplatin: mechanisms and potential","volume":"18","author":"Zhou","year":"2025","journal-title":"Pharm. (Basel)"},{"key":"B274","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","article-title":"The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells","volume":"32","author":"Zhu","year":"2015","journal-title":"Pharm. Res."},{"key":"B275","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1080\/10717544.2021.1995080","article-title":"Redox-sensitive iodinated polymersomes carrying histone deacetylase inhibitor as a dual-functional nano-radiosensitizer for enhanced radiotherapy of breast cancer","volume":"28","author":"Zhu","year":"2021","journal-title":"Drug Deliv."},{"key":"B276","doi-asserted-by":"publisher","first-page":"114065","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1951750\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:41:47Z","timestamp":1790667707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1951750\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":267,"alternative-id":["10.3389\/fcell.2026.1951750"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1951750","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1951750"}}